In the inter partes review (IPR) proceeding between Mylan Pharmaceuticals, Inc. v. Allergan, Inc., before the Patent Trial and Appeal Board (PTAB), counsel representing the Patent Owner raised a defense that, if successful, could circumvent IPR proceedings and shield patents from post-grant review. Allergan, whose patents for the drug Restasis which are the subject of the IPR proceeding challenging their validity, recently struck a deal with the St. Regis Mohawk Tribe, transferring its patent rights in exchange for a license. Last week, counsel representing the Tribe, a sovereign nation, raised the defense of sovereign immunity, arguing its immunity places the patents at issue beyond the PTAB’s authority. The Tribe has until September 22 to file its brief on the immunity defense.
Published in
Patent

James Ryan
Mr. Ryan earned his bachelor’s degree in Computer and Information Science from Minnesota State University and his law degree, with honors, from St. Thomas University School of Law. Mr. Ryan is admitted to practice law in the State of Florida.
Latest from James Ryan
- December 31, 2017 Deadline to Re-Register for Copyright Infringement Protection
- December 31, 2017 Deadline to Re-Register for Copyright Infringement Protection
- Important Copyright Notice
- Supreme Court grants district courts the discretion to award enhanced damages for egregious patent infringement
- Federal Circuit Broadens the Category of Divided Patent Infringement in Akamai v. Limelight